The DNA sequences of the 16S rRNA, secA1, gyrB, rpoB and hsp65 genes of 25 Nocardia isolates studied have been submitted to GenBank database (accession numbers KT985911 to KT985935, KU052160 to KU052184, KU052085 to KU052109, KU052135 to KU052159 and KU052110 to KU052134 for the above five genes, respectively.

Introduction {#sec001}
============

*Nocardia* species are ubiquitous environmental bacteria that cause suppurative infections in humans, including in the lung, central nervous system and skin \[[@pone.0147487.ref001]\]. Nocardiosis typically occurs in immunosuppressed patients such as organ and stem cell transplantation, and malignancy, but also affects immunocompetent hosts \[[@pone.0147487.ref002]--[@pone.0147487.ref004]\]. Since there are species-specific differences with regard to geography and disease patterns, identification of *Nocardia* to species level is important to determine both epidemiology and clinical associations.

Conventional culture identification of *Nocardia* based on phenotypic methods and distinct (but limited) antimicrobial susceptibility profiles lacks sufficient discriminatory power, is slow and time-consuming and requires staff expertise \[[@pone.0147487.ref005], [@pone.0147487.ref006]\]. Thus identification of *Nocardia* isolates by molecular methods is increasingly used, of which PCR-based methods combined with DNA sequencing are the most popular. Of these, 16S rRNA gene sequencing is considered the "gold-standard" \[[@pone.0147487.ref006], [@pone.0147487.ref007]\]. However, 16S rRNA gene sequencing is unable to distinguish certain closely related species due to insufficient interspecies gene polymorphisms \[[@pone.0147487.ref006], [@pone.0147487.ref008]\], whilst also unable to resolve certain species, e.g. *Nocardia nova* due to the presence of multiple yet different copies of this gene \[[@pone.0147487.ref009]\]. To overcome this limitation, other gene polymorphisms have been evaluated, such as those within the β-subunit of the type II DNA topoisomerase gene (*gyrB*) \[[@pone.0147487.ref010], [@pone.0147487.ref011]\], the subunit A of the SecA preprotein translocase gene (*secA1*) \[[@pone.0147487.ref012], [@pone.0147487.ref013]\], the 65-kDa heat shock protein gene (*hsp65*) \[[@pone.0147487.ref014], [@pone.0147487.ref015]\], and the β subunit of DNA-dependent RNA polymerase gene (*rpoB*) \[[@pone.0147487.ref011]\]. A multilocus sequence analysis (MLSA) scheme analyzing sequence polymorphisms of multiple *Nocardia* genes was reported to be accurate not only for the identification of known *Nocardia* species but the unveiling of novel species \[[@pone.0147487.ref016]\].

Other than genomic approaches, proteomic methods, most notably matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) method, have also been evaluated to identify *Nocardia* species in clinical laboratories. However, the presence of aliphatic acids in the cell wall of *Nocardia* has posed an obstacle in achieving satisfactory protein profiles. Furthermore, although improvements are continuing, many databases provided by commercial MALDI-TOF MS systems contain only a limited number of archived *Nocardia* spectral profiles \[[@pone.0147487.ref017], [@pone.0147487.ref018]\]. Previous studies have reported identification to species level in only 14.9--80.4% of isolates \[[@pone.0147487.ref018]--[@pone.0147487.ref023]\]. Complementation with profiles provided by "in-house" databases, which in turn relies on knowledge of local epidemiology, hence may assist with identification to the species, or even, genus level.

In the present study, we firstly evaluated a published MLSA scheme \[[@pone.0147487.ref016]\] employing polymorphisms in the 16S rRNA, *gyrB*, *secA1*, *hsp65* and *rpoB* loci for the identification of clinical *Nocardia* isolates in our laboratory; and secondly, determined the ability of MALDI-TOF MS for species assignment. Results were compared to those obtained by the 5'-end 606 bp 16S rRNA gene sequencing. An "in-house" database of *Nocardia* protein profiles was established and evaluated for its ability to complement a commercial database for identification of *Nocardia* species.

Materials and Methods {#sec002}
=====================

Ethics {#sec003}
------

The study was approved by the Human Research Ethics Committee of Peking Union Medical College Hospital (PUMCHBC-C-2-Q01-1). Written informed consent was obtained from patients for the use of the samples in research.

*Nocardia* strains and reference sequences {#sec004}
------------------------------------------

Twenty-five clinical strains were studied in the evaluation of the ability of an MLSA scheme \[[@pone.0147487.ref016]\] and MALDI-TOF MS to provide species identification. Isolates were cultured from patients admitted to the Peking Union Medical College Hospital from January 2009 to January 2015 ([Table 1](#pone.0147487.t001){ref-type="table"}). All isolates were identified by standard phenotypic methods \[[@pone.0147487.ref024]\]. Isolates were stored at -80°C and subcultured on Columbia blood agar for 72 h to 96 h at 37°C to ensure adequate growth before study.

10.1371/journal.pone.0147487.t001

###### *Nocardia* isolates examined (n = 25) in the present study.

![](pone.0147487.t001){#pone.0147487.t001g}

  Strains no.   Age (years)   Gender   Medical department   Specimen type         Immuno-Compromised (Yes/No)
  ------------- ------------- -------- -------------------- --------------------- -----------------------------
  PUNC001       53            Male     Outpatient           PICC Drainage         No
  PUNC002       70            Female   Gastroenterology     Sputum                No
  PUNC003       53            Male     Immunology           Lung tissue           Yes
  PUNC004       64            Male     Respiratory          Subcutaneous nodule   Yes
  PUNC005       72            Male     Nephrology           Sputum                Yes
  PUNC006       31            Female   Emergency            Sputum                Yes
  PUNC007       43            Female   Thoracic Surgery     Sputum                No
  PUNC008       50            Male     Emergency            Hydrothorax fluid     Yes
  PUNC009       67            Male     Emergency            Sputum                No
  PUNC010       70            Male     Respiratory          Sputum                Yes
  PUNC011       70            Male     Respiratory          Sputum                No
  PUNC012       51            Male     Respiratory          Sputum                No
  PUNC013       76            Male     Respiratory          Sputum                No
  PUNC014       45            Female   Respiratory          Lung tissue           No
  PUNC015       61            Female   Immunology           Hydrothorax fluid     Yes
  PUNC016       81            Male     Outpatient           Sputum                No
  PUNC017       71            Male     Respiratory          Sputum                Yes
  PUNC018       56            Female   Respiratory          BALF                  Yes
  PUNC019       53            Male     Orthopedics          Pus                   No
  PUNC020       46            Female   Outpatient           Pus                   No
  PUNC021       57            Male     Immunology           Sputum                Yes
  PUNC022       32            Female   Respiratory          BALF                  Yes
  PUNC023       45            Male     Emergency            Sputum                No
  PUNC024       37            Male     Emergency            Pus                   No
  PUNC025       65            Male     Emergency            Sputum                No

Abbreviations: PICC, peripherally inserted central catheter; BALF, bronchoalveolar lavage fluid; SLE, systemic lupus erythematosus; COPD, chronic obstructive pulmonary disease.

In addition, the GenBank sequences of 16S rRNA, *gyrB*, *secA1*, *hsp65* and *rpoB* loci corresponding to 20 *Nocardia* type strains were studied as the "validation cohort" to determine the ability of the MLSA typing scheme \[[@pone.0147487.ref007], [@pone.0147487.ref016]\] to identify *Nocardia* clinical isolates collected (see [S1 Table](#pone.0147487.s001){ref-type="supplementary-material"}).

DNA extraction, PCR amplification and sequencing {#sec005}
------------------------------------------------

DNA extraction of all isolates was performed as previously described \[[@pone.0147487.ref008]\]. The *Nocardia* 16S rRNA gene was amplified using the primer pair 27F and 1522R \[[@pone.0147487.ref025]\]. The *Nocardia gyrB*, *secA1*, *hsp65* and *rpoB* genes were amplified as previously described \[[@pone.0147487.ref016]\]. In all cases, amplified PCR products were sequenced in both directions using the amplification primers on the ABI 3730XL platform (Applied Biosystems, Foster City, CA).

Species identification by the 5'-end 606 bp partial 16S rRNA gene sequencing and MLSA {#sec006}
-------------------------------------------------------------------------------------

Molecular-based species identification was initially carried out by analysis of the 5'-end 606 bp partial 16S rRNA gene sequences as described using a percentage similarity (or identity) score of ≥ 99% as the criterion to strictly classify an isolate to species level \[[@pone.0147487.ref007]\]. MLSA was then carried out examining nucleotide polymorphisms in the partial 16S rRNA gene at 5'-end (462 bp), as well as the *secA1* (445 bp), *gyrB* (482 bp), *rpoB* (400 bp) and *hsp65* (401 bp) genes \[[@pone.0147487.ref016]\]. The concatenated *gyrB*-16S-*secA1*-*hsp65*-*rpoB* sequences (2190 bp) were then used for phylogenetic analysis by the maximum-likelihood algorithm based on the Tamura-Nei model \[[@pone.0147487.ref026]\] with 1000 bootstrap replication to ensure robustness using MEGA software (version 6.0, MEGA Inc., Englewood, NJ). DnaSP software (version 5.1, University of Barcelona, Spain) was used to assess the haplotypes of each gene \[[@pone.0147487.ref027]\]. Determining of potential subtypes of *N*. *cyriacigeorgica* isolates was further carried out by analysis of the *Nocardia hsp65* gene as previously described \[[@pone.0147487.ref028], [@pone.0147487.ref029]\].

Establishment and validation of an "in-house" *Nocardia* mass spectrum database for MALDI-TOF MS {#sec007}
------------------------------------------------------------------------------------------------

All *Nocardia* isolates was pretreated using a mechanical disruption-ethanol extraction method as described by Dunne *et al*. \[[@pone.0147487.ref030]\]. MALDI-TOF MS analysis of 25 clinical *Nocardia strains* was first carried by the Bruker Autoflex Speed TOF/TOF MS system using Biotyper software version 3.1 (db 4613, Bruker Daltonics, Billerica, USA) according to the manufacturer's instructions. A spectral score of \< 1.70 was considered not to provide reliable identification. A score of ≥ 1.70 but \< 2.00 indicated identification at the genus level, and a score of ≥ 2.00 was considered identification at the species level \[[@pone.0147487.ref018]\].

Because the identification results using the manufacturer-provided Biotyper database was unsatisfactory (see "[Results](#sec010){ref-type="sec"}" below), five of the 25 clinical isolates representing five different *Nocardia* species (as identified by DNA sequencing in the present study---strain ID no. PUNC001 (*Nocardia farcinica*), PUNC002 (*Nocardia abscessus*), PUNC006 (*Nocardia cyriacigeorgica*), PUNC020 (*Nocardia wallacei*), and PUNC024 (*Nocardia otitidiscaviarum*); [Table 2](#pone.0147487.t002){ref-type="table"}) were used to generate an "in-house" mass spectrum fingerprint database following the methodology of Segawa *et al*. \[[@pone.0147487.ref018]\]. Each isolate was analyzed in replicates of eight (ie. inoculated in eight spots on the target plate), and each spot was interrogated three times. This procedure was repeated at least once on a different occasion under identical test conditions. The resulting data were averaged using the Biotyper software v3.1 (Bruker Daltonics), a single mass spectrum representing each isolate was generated, and the resultant profiles established as a small "in-house" database.

10.1371/journal.pone.0147487.t002

###### Identification results of 25 *Nocardia* clinical isolates by DNA sequencing and MALDI-TOF MS after interrogation against the Biotyper database (version 3.1) and the "in-house" database.
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  Strain ID no.                                                                                                  Identification by MLSA    Identification by conventional methods   Identification by MALDI-TOF MS[^a^](#t002fn002){ref-type="table-fn"}   
  -------------------------------------------------------------------------------------------------------------- ------------------------- ---------------------------------------- ---------------------------------------------------------------------- -------
  **Isolates used for establishment of "in-house" mass spectra database (no. = 5)**                                                                                                                                                                        
  PUNC001^a^                                                                                                     *N*. *farcinica*          *Nocardia* sp.                           N/A                                                                    N/A
  PUNC002^a^                                                                                                     *N*. *abscessus*          *Nocardia* sp.                           N/A                                                                    N/A
  PUNC006^a^                                                                                                     *N*. *cyriacigeorgica*    *Nocardia* sp.                           N/A                                                                    N/A
  PUNC020^a^                                                                                                     *N*. *wallacei*           *Nocardia* sp.                           N/A                                                                    N/A
  PUNC024^a^                                                                                                     *N*. *otitidiscaviarum*   *N*. *otitidiscaviarum*                  N/A                                                                    N/A
  **Isolates used for validation of the MALDI-TOF MS system[^a^](#t002fn002){ref-type="table-fn"} (no. = 20)**                                                                                                                                             
  PUNC003                                                                                                        *N*. *cyriacigeorgica*    *N*. *cyriacigeorgica*                   *N*. *cyriacigeorgica*                                                 2.160
  PUNC004                                                                                                        *N*. *farcinica*          *Nocardia* sp.                           *N*. *farcinica*                                                       2.332
  PUNC005                                                                                                        *N*. *cyriacigeorgica*    *Nocardia* sp.                           *N*. *cyriacigeorgica*                                                 2.129
  PUNC007                                                                                                        *N*. *cyriacigeorgica*    *N*. *asteroides*                        *N*. *cyriacigeorgica*                                                 2.393
  PUNC008                                                                                                        *N*. *farcinica*          *Nocardia* sp.                           *N*. *farcinica*                                                       2.411
  PUNC009                                                                                                        *N*. *farcinica*          *N*. *farcinica*                         *N*. *farcinica*                                                       2.284
  PUNC010                                                                                                        *N*. *cyriacigeorgica*    *N*. *cyriacigeorgica*                   *N*. *cyriacigeorgica*                                                 2.011
  PUNC011                                                                                                        *N*. *cyriacigeorgica*    *N*. *cyriacigeorgica*                   *N*. *cyriacigeorgica*                                                 2.232
  PUNC012                                                                                                        *N*. *farcinica*          *Nocardia* sp.                           *N*. *farcinica*                                                       2.196
  PUNC013                                                                                                        *N*. *cyriacigeorgica*    *N*. *cyriacigeorgica*                   *N*. *cyriacigeorgica*                                                 2.126
  PUNC014                                                                                                        *N*. *farcinica*          *N*. *farcinica*                         *N*. *farcinica*                                                       2.124
  PUNC015                                                                                                        *N*. *farcinica*          *N*. *farcinica*                         *N*. *farcinica*                                                       2.055
  PUNC016                                                                                                        *N*. *cyriacigeorgica*    *N*. *cyriacigeorgica*                   *N*. *cyriacigeorgica*                                                 2.422
  PUNC017                                                                                                        *N*. *abscessus*          *N*. *abscessus*                         *N*. *abscessus*                                                       1.894
  PUNC018                                                                                                        *N*. *cyriacigeorgica*    *Nocardia* sp.                           *N*. *cyriacigeorgica*                                                 2.307
  PUNC019                                                                                                        *N*. *cyriacigeorgica*    *N*. *cyriacigeorgica*                   *N*. *cyriacigeorgica*                                                 2.145
  PUNC021                                                                                                        *N*. *cyriacigeorgica*    *Nocardia* sp.                           *N*. *cyriacigeorgica*                                                 2.079
  PUNC022                                                                                                        *N*. *farcinica*          *Nocardia* sp.                           *N*. *farcinica*                                                       2.498
  PUNC023                                                                                                        *N*. *farcinica*          *N*. *farcinica*                         *N*. *farcinica*                                                       2.431
  PUNC025                                                                                                        *N*. *cyriacigeorgica*    *Nocardia* sp.                           *N*. *cyriacigeorgica*                                                 2.052

Abbreviation: N/A, not applicable.

^a^ Results by using the Bruker Biotyper version 3.1 (Bruker Daltonics) complementation with the "in-house" database (see [Materials and Methods](#sec002){ref-type="sec"} for detail).

The 20 remaining clinical isolates were then analyzed against the Biotyper version 3.1 database (Bruker Daltonics) complemented with the "in-house" database. The technicians performing the analysis were blinded to the DNA sequencing results to avoid potential bias.

A main spectrum profile (MSP) dendrogram was further constructed using spectra of 25 *Nocardia* clinical strains in this study along with 37 reference spectra of 32 *Nocardia* species already contained in the Biotyper version 3.1 database for analysis of genetic relatedness.

Review for publications on validation of MALDI-TOF MS in identification of *Nocardia* species {#sec008}
---------------------------------------------------------------------------------------------

Key words "*Nocardia*" and "matrix-assisted laser desorption ionization-time of flight mass spectrometry" were used to search related publications in English archived in NCBI PubMed database (<http://www.ncbi.nlm.nih.gov/pubmed>, till Dec 31^st^, 2015). All complete articles of the search (16 publications in all) were screened. After excluding case reports, six publications were reviewed in detail.

GenBank accession numbers {#sec009}
-------------------------

The DNA sequences of the full-length 16S rRNA, *secA1*, *gyrB*, *rpoB* and *hsp65* genes of 25 *Nocardia* isolates studied have been submitted to GenBank database (accession numbers KT985911 to KT985935, KU052160 to KU052184, KU052085 to KU052109, KU052135 to KU052159 and KU052110 to KU052134 for the above five genes, respectively, [S2 Table](#pone.0147487.s002){ref-type="supplementary-material"}).

Results {#sec010}
=======

Identification by the 5'-end 606 bp partial 16S rRNA gene sequencing {#sec011}
--------------------------------------------------------------------

Of 25 *Nocardia* clinical strains, 24 isolates representing four *Nocardia* species were identified unambiguously by the 5'-end 606 bp partial 16S rRNA gene sequencing. *N*. *cyriacigeorgica* (n = 12, 48%) and *N*. *farcinica* (n = 9, 36%) were the most common species, followed by *N*. *abscessus* (n = 2, 8%) and *N*. *otitidiscaviarum* (n = 1, 4%). However, the 5'-end 606 bp partial 16S rRNA gene sequence of strain PUNC020 showed 99% sequence similarity to both *N*. *wallacei* type strain DSM 45136^T^ (606/606, 100%) and *Nocardia transvalensis* type strain NRRL B-16037^T^ (600/606, 99.0%), though was identical to the former.

MLSA {#sec012}
----

Phylogenetic analysis of concatenated *gyrB*-16S-*secA1*-*hsp65*-*rpoB* sequences obtained from the 25 clinical isolates and 20 *Nocardia* type strain sequences clearly revealed five major clusters with bootstrap threshold values of ≥ 90% ([Fig 1](#pone.0147487.g001){ref-type="fig"}). Each cluster corresponded to a unique *Nocardia* species, ie. *N*. *cyriacigeorgica*, *N*. *otitidiscaviarum*, *N*. *farcinica*, and *N*. *abscessus*), except for clinical strain PUNC020 that was clustered together with type strains of *N*. *wallacei* and *N*. *transvalensis*. As strain PUNC020 was more phylogenetically closely related to *N*. *wallacei* strain DSM 45136^T^ compared with *N*. *transvalensis* strain NRRL B-16037^T^ ([Fig 1](#pone.0147487.g001){ref-type="fig"}), the isolate was assigned as *N*. *wallacei*.

![Phylogenetic trees are shown and were conducted using the maximum-likelihood method.\
**Fig 1a.** Phylogenetic tree based on the concatenated *gyrB*-16S-*secA1*-*hsp65*-*rpoB* sequences of 25 *Nocardia* clinical isolates and 20 *Nocardia* type strains, using *Gordonia bronchialis* strain ATCC 25592^T^ as an outgroup ([S1 Table](#pone.0147487.s001){ref-type="supplementary-material"}). **Fig 1b.** Phylogenetic tree based on the *hsp65* gene sequences of 12 *N*. *cyriacigeorgica* clinical isolates and nine *Nocardia cyriacigeorgica* isolates whose genotypes have previously been determined by Schlaberg *et al*. \[[@pone.0147487.ref029]\] using the sequence of a *Nocardia farcinica* strain as an outgroup.](pone.0147487.g001){#pone.0147487.g001}

Twelve *N*. *cyriacigeorgica* clinical isolates could further be classified into three subgroups: subgroup a (n = 6), b (n = 4) and c (n = 2), ([Fig 1A](#pone.0147487.g001){ref-type="fig"}). Comparing with results obtained by *N*. *cyriacigeorgica* genotyping using sequence analysis of the *hsp65* gene \[[@pone.0147487.ref028], [@pone.0147487.ref029]\], isolates belonging to *N*. *cyriacigeorgica* MLSA subgroups a, b and c corresponded to *N*. *cyriacigeorgica hsp65* genotype I, III and II, respectively ([Fig 1B](#pone.0147487.g001){ref-type="fig"}).

Overall, it was observed that the *rpoB*, *gyrB* and *secA1* genes were the most polymorphic (14 to 16 haplotypes identified amongst 25 clinical strains, haplotype diversity ≥ 0.950), followed by *hsp65* (10 haplotypes, haplotype diversity = 0.837), whilst the partial 16S rRNA gene was the least polymorphic (five haplotypes, haplotype diversity = 0.657) ([Table 3](#pone.0147487.t003){ref-type="table"} and [S2 Table](#pone.0147487.s002){ref-type="supplementary-material"}). Different degrees of intra-species micro-heterogeneity of different genes were also observed ([Table 3](#pone.0147487.t003){ref-type="table"}). *N*. *cyriacigeorgica* isolates generally exhibited higher intra-species diversity than other species e.g. *N*. *farcinica* ([Table 3](#pone.0147487.t003){ref-type="table"}).

10.1371/journal.pone.0147487.t003

###### Genetic polymorphisms contained within the 16S rRNA, *gyrB*, *secA1*, *hsp65* and *rpoB* genes for 25 clinical *Nocardia* isolates studied.
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  Characters                            *gyrB*    16S rRNA gene   *secA1*   *hsp65*   *rpoB*
  ------------------------------------- --------- --------------- --------- --------- ---------
  **All clinical isolates (n = 25)**                                                  
  No. of haplotypes                     16        5               14        10        16
  Haplotype diversity                   0.957     0.657           0.950     0.837     0.963
  ***N*. *cyriacigeorgica* (n = 12)**                                                 
  No. of haplotypes                     8         1               6         5         8
  Haplotype diversity                   0\. 924   N/A             0\. 848   0\. 803   0\. 924
  ***N*. *farcinica* (n = 9)**                                                        
  No. of haplotypes                     4         1               5         1         5
  Haplotype diversity                   0\. 778   N/A             0\. 889   N/A       0\. 861

Abbreviation: N/A, not applicable.

Improvement of MALDI-TOF MS identification capacity by the "in-house" database {#sec013}
------------------------------------------------------------------------------

Of the five species identified by the 5'-end 606 bp partial 16S rRNA gene sequencing and MLSA from the present study which we selected to establish a mini "in-house" database, representation of four species (*N*. *cyriacigeorgica*, *N*. *farcinica*, *N*. *abscessus* and *N*. *otitidiscaviarum*) was already included in the Biotyper version 3.1 database (Bruker Daltonics); however, *N*. *wallacei* was not represented. When all 25 clinical isolates were interrogated using only the Biotyper database, only eight of 25 (32%) isolates was identified to genus level, none (0%) to species level, and 17 isolates were not identified (68%).

Using the "in-house" database to complement the Biotyper database, 19 of 20 (95%) *Nocardia* clinical isolates were correctly identified to species level with scores of ≥ 2.0 ([Table 2](#pone.0147487.t002){ref-type="table"}). *N*. *abscessus* strain PUNC017, which yielded a MALDI-TOF MS score of 1.894, was identified to genus level ([Table 2](#pone.0147487.t002){ref-type="table"}).

The MSP dendrogram indicated that the spectral profile of clinical isolates were distinct from the corresponding reference spectra for its species in the Biotyper database ([Fig 2](#pone.0147487.g002){ref-type="fig"}). The mass spectra differences between *N*. *abscessus* strain PUNC002 (for establishment of the "in-house" database) and *N*. *abscessus* strain PUNC017 (for test of the "in-house" database) also resulted in failure in identifying strain PUNC017 to specie level using the "in-house" database ([Fig 2](#pone.0147487.g002){ref-type="fig"}). Therefore, the mass spectra of strain PUNC017 was incorporated into the "in-house" database for future study. Similar divergence of mass spectra were also noted in *N*. *otitidiscaviarum* for clinical strain PUNC024 versus strain VA_01844_09 and type strain DSM 43242^T^ that included in the commercial database ([Fig 2](#pone.0147487.g002){ref-type="fig"}), which led to failure of identifying strain PUNC024 to species level using the commercial database.

![The main spectrum profile (MSP) dendrogram constructed using spectra of 25 *Nocardia* clinical strains along with 37 reference spectra of 32 *Nocardia* species contained in the original Biotyper database (version 3.1; Bruker).\
Strain identification numbers of clinical isolates collected in the present study are shown underlined, and isolates used for establishment of the "in-house" database was labeled with asterisks.](pone.0147487.g002){#pone.0147487.g002}

Literature review for *Nocardia* identification by MALDI-TOF MS {#sec014}
---------------------------------------------------------------

Of six studies reviewed, five had evaluated the Bruker Biotyper commercial database (version 3.1 or 3.0.2) and one, an Andromas (Paris, France) system ([Table 4](#pone.0147487.t004){ref-type="table"}). The Biotyper database only correctly identified 14.9--52.8% of isolates to species level and an additional 6.9--52.7% of isolates to genus level. The performance of Andromas system (Paris, France) was better (80.4% to species level and 17.6% to genus level). Three studies further developed local "in-house" databases, and the correct identification rate was significantly improved to 79.1--90.6% to species level and an additional 4.7--11.5% to genus level ([Table 4](#pone.0147487.t004){ref-type="table"}).

10.1371/journal.pone.0147487.t004

###### Review of publications for evaluation of MALDI-TOF MS for the identification of *Nocardia* species.
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                                                                                                                                                                           Commercial DB                                    \"In-house\" DB                                                                                              
  ------------------------------ --------------------------------------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ -------- -------------------------------------------------- ----------------------------
  Bruker Autoflex Speed          MLSA                                    ≥ 2.0/\< 2.0 and ≥ 1.7                           See note[^a^](#t004fn002){ref-type="table-fn"}   BioTyper ver. 3.1                                0%/32.0%[^a^](#t004fn002){ref-type="table-fn"}   5/5      95.0%/5.0%[^a^](#t004fn002){ref-type="table-fn"}   This study
  Bruker microflex LT            16S rRNA gene and conventional          ≥ 2.0/\< 2.0 and ≥ 1.7                           148/15                                           BioTyper ver. 3.1                                41.9%/15.5%                                      232/53   89.9%/4.7%                                         \[[@pone.0147487.ref023]\]
  Bruker (Model not specified)   16S rRNA, *hsp65* and *secA1* genes     ≥ 1.9/\< 1.9 and ≥ 1.7                           87/25                                            BioTyper ver. 3.1                                52.8%/6.9%                                       13/13    82.8%/11.5%                                        \[[@pone.0147487.ref022]\]
  Bruker microflex LT            16S rRNA gene and conventional          ≥ 2.0/\< 2.0 and ≥ 1.7                           64/22                                            BioTyper ver. 3.1                                15.6%/25.0%                                      192/73   90.6%/9.4%                                         \[[@pone.0147487.ref018]\]
  Bruker microflex LT            16S rRNA and *secA1* genes              ≥ 2.0/\< 2.0 and ≥ 1.7                           74/14                                            BioTyper ver. 3.1                                14.9%/52.7%                                      ND       ND                                                 \[[@pone.0147487.ref019]\]
  Andromas                       16S rRNA, *hsp65* genes, conventional   See note[^b^](#t004fn003){ref-type="table-fn"}   51/12                                            See note[^b^](#t004fn003){ref-type="table-fn"}   80.4%/17.6%                                      ND       ND                                                 \[[@pone.0147487.ref021]\]
  Bruker microflex LT            16S rRNA gene and conventional          ≥ 2.0/\< 2.0 and ≥ 1.7                           43/9                                             BioTyper ver. 3.0.2                              23.3%/20.9%                                      110/17   79.1%/9.3%                                         \[[@pone.0147487.ref020]\]

Abbreviations: ID, identification; Ni/Ns, number of isolates/number of species; DB, database; MLSA, multilocus sequence analysis.

^a^ In the present study, all 25 *Nocardia* clinical isolates collected were involved for validation of the commercial Bruker Biotyper database. While for the \"in-house\" database, five of the 25 *Nocardia* isolates were used for databased development, and the rest 20 isolates were used for \"in-house\" database validation. See details in [Methods](#sec002){ref-type="sec"} section.

^b^ An Andromas database (database version not specified) was employed in the study by Farfour *et al*. Criteria for correct identification to species level: percentage of common peaks is ≥ 68% and more than 10% difference between the first two best-match species. Criteria for correct identification to genus level: percentage of common peaks is ≥ 68% yet less than 10% difference between the first two best-match species.

A proposed algorithm for species identification of *Nocardia* in clinical laboratories {#sec015}
--------------------------------------------------------------------------------------

Although the MLSA scheme was definitively able to assign species, identify novel species, and to differentiate within species, it has the disadvantage of relatively high costs, and requiring staff time for analysis of results. We propose an algorithm for species identification of *Nocardia* in the clinical laboratory ([Fig 3](#pone.0147487.g003){ref-type="fig"}), recommending that identification by MALDI-TOF MS using a database complemented by "in-house" protein profiles be attempted in the initial instance. For those isolates that cannot be identified to species level by MALDI-TOF MS, the 5'-end 606 bp partial 16S rRNA sequencing may be attempted. For any isolates with \< 99% gene sequence similarity to a known archived strain sequence or those with two or more "best hit" species identities, MLSA could be undertaken for a definitive identification.

![Proposed algorithm for laboratory identification of *Nocardia* isolates (solid lines) and establishment and expansion of ongoing "in-house" mass spectrum database (dashed lines).](pone.0147487.g003){#pone.0147487.g003}

Discussion {#sec016}
==========

To date, more than 50 species of pathogenic *Nocardia* have been identified \[[@pone.0147487.ref031]\]. Since there are differences in prevalence of species between geographic regions, knowledge of species distribution is important. In the present study, *N*. *cyriacigeorgica* and *N*. *farcinica* were the most commonly encountered species, similar to that in Canada \[[@pone.0147487.ref016]\], but in contrast to a report from Taiwan where *Nocardia brasiliensis* was the most common \[[@pone.0147487.ref032]\]. In comparison, *Nocardia asteroides* was reported to be predominant in Switzerland \[[@pone.0147487.ref031]\], while *N*. *nova* was predominant in Australia \[[@pone.0147487.ref007]\].

Most studies examining identification of *Nocardia* have indicated that molecular techniques are required to achieve species assignment \[[@pone.0147487.ref006], [@pone.0147487.ref016], [@pone.0147487.ref031], [@pone.0147487.ref032]\]. Although polymorphisms in the 5'-end partial 16S rRNA gene is widely used to discriminate between *Nocardia* species, misidentification may occur due to high sequence similarity between certain species \[[@pone.0147487.ref006], [@pone.0147487.ref007], [@pone.0147487.ref016], [@pone.0147487.ref033]\], as exemplified by inability to distinguish *N*. *wallacei* from *N*. *transvalensis* in the present study, or due to multiple different copies of this gene, such as that in *N*. *nova* \[[@pone.0147487.ref009]\]. *N*. *wallacei* is very closely related to *N*. *transvalensis* and indeed was previously classified within the *N*. *transvalensis* complex. Using a more discriminatory method, in this case, a 5-locus MLSA, *N*. *wallacei* was assigned as an individual species, which supported findings by Conville *et al*. \[[@pone.0147487.ref012]\].

In this context then, MLSA has been carried out as an alternative technique for the identification of *Nocardia*. The most commonly used genes have been the 16S rRNA, *secA1*, *gyrB*, *rpoB* and *hsp65* genes. Different studies may employ different combination of the genes \[[@pone.0147487.ref011], [@pone.0147487.ref016], [@pone.0147487.ref034]\], yet it is notable that no single gene locus sequencing is sufficient to resolve a substantial number of *Nocardia* species \[[@pone.0147487.ref016]\]. In addition, the MLSA scheme can be used for examining intra-species genetic diversity \[[@pone.0147487.ref010], [@pone.0147487.ref011], [@pone.0147487.ref013]\]. Using this approach, Carrasco *et al*. has reported that species *N*. *nova* had highest intra-species heterogeneity, followed by *N*. *cyriacigeorgica* and *N*. *abscessus*, while *N*. *farcinica* was more conserved \[[@pone.0147487.ref011]\]. Although the diversity of *N*. *abscessus* and *N*. *nova* were not compared in this study due to only a limited number of isolates studied, we similarly found genetic heterogeneity within *N*. *cyriacigeorgica* where three subgroups were identified. Of note, these subgroups correspond to three *hsp65* genotypes proposed in previous studies \[[@pone.0147487.ref028], [@pone.0147487.ref029]\]. In the diagnostic algorithm proposed ([Fig 3](#pone.0147487.g003){ref-type="fig"}) for laboratory identification of *Nocardia*, MLSA has good clinical utility in definitive confirmative of species.

Application of sequencing-based methods in the routine work of clinical laboratories is restricted by high costs and the need for on-site sequencing facilities which potentially affect turn-around times. The recent introduction of MALDI-TOF MS platforms in clinical laboratories has revolutionized diagnostic microbiology \[[@pone.0147487.ref035]\]. However, its application in identification of *Nocardia* species required extra protein-extraction pretreatment of isolates \[[@pone.0147487.ref017], [@pone.0147487.ref030]\], and more importantly, may be limited by insufficient archiving of reference spectra within commercial MALDI-TOF MS databases \[[@pone.0147487.ref017]--[@pone.0147487.ref020]\]. In this study, the MSP analysis indicated significant differences between spectra of the clinical isolates studied and reference spectra of corresponding species contained in the Biotyper version 3.1 database (Bruker Daltonics), which yielded suboptimal results in species identification when used as the only database. However, the establishment of even a small "in-house" database significantly improved the identification capacity of the MALDI-TOF MS system, as also found previously \[[@pone.0147487.ref018], [@pone.0147487.ref020], [@pone.0147487.ref022], [@pone.0147487.ref023]\]. To improve the identification capacity of MALDI-TOF MS, it is important for MS databases to contain more reference mass spectra from type strains of different bacteria species, and also spectra representing different strains of the same species \[[@pone.0147487.ref035]\], as strains of the same species may have divergent mass spectra e.g. the case of *N*. *abscessus* clinical strain PUNC002 and PUNC017 found in the present study. With an ongoing expanded "in-house" database representing species that are the more frequently encountered, the utility and practicality of MALDI-TOF MS for *Nocardia* identification will be improved. However, before expanding any "in-house" mass spectrum database, we recommend that *Nocardia* isolates be analyzed by MLSA to ensure the high-quality of the "in-house" database ([Fig 3](#pone.0147487.g003){ref-type="fig"}). Moreover, comparing to MLSA, the MALDI-TOF MS system was unable to cluster *N*. *cyriacigeorgica* into subgroups. In this regard, MLSA is superior to MALDI-TOF MS for subgrouping *N*. *cyriacigeorgica*. Further studies addressing differences in MS profiles between *N*. *cyriacigeorgica* strains are warranted.

The major limitation of the current study is that relatively few isolates representing a small number of species was examined, and all isolates were from a single center and hence may not be generalizable across centers in China. Continuous expansion of the MALDI-TOF MS databases to include more species is necessary.

Conclusions {#sec017}
===========

In conclusion, we have evaluated MLSA scheme and MALDI-TOF MS for identification of *Nocardia* clinical isolates. MLSA showed superior discriminatory power compared with the 5'-end 606bp partial 16S rRNA gene sequencing for species identification of *Nocardia*. MALDI-TOF MS has good utility in rapidly and accurately providing species identification but is contingent on building up a robust library of reference spectra.
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